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Abstract
Background: Sublethal doses of whole brain irradiation (WBI) are commonly administered therapeutically and
frequently result in late delayed radiation injuries, manifesting as severe and irreversible cognitive impairment.
Neural progenitors within the subgranular zone (SGZ) of the dentate gyrus are among the most radiosensitive cell
types in the adult brain and are known to participate in hippocampal plasticity and normal cognitive function.
These progenitors and the specialized SZG microenvironment required for neuronal differentiation are the source
of neurogenic potential in the adult dentate gyrus, and provide a continuous supply of immature neurons which
may then migrate into the adjacent granule cell layer to become mature granule cell neurons. The extreme
radiosensitivity of these progenitors and the SGZ microenvironment suggests the hippocampus as a prime target
for radiation-induced cognitive impairment. The brain renin-angiotensin system (RAS) has previously been
implicated as a potent modulator of neurogenesis within the SGZ and selective RAS inhibitors have been
implicated as mitigators of radiation brain injury. Here we investigate the angiotensin converting enzyme (ACE)
inhibitor, ramipril, as a mitigator of radiation injury in this context.
Methods: Adult male Fisher 344 rats received WBI at doses of 10 Gy and 15 Gy. Ramipril was administered
beginning 24 hours post-WBI and maintained continuously for 12 weeks.
Results: Ramipril produced small but significant reductions in the deleterious effects of radiation on progenitor
proliferation and neuronal differentiation in the rat dentate gyrus following 10 Gy-WBI, but was not effective
following 15 Gy-WBI. Ramipril also reduced the basal rate of neurogenesis within the SGZ in unirradiated control
rats.
Conclusions: Our results indicate that chronic ACE inhibition with ramipril, initiated 24 hours post-irradiation, may
reduce apoptosis among SGZ progenitors and/or inflammatory disruption of neurogenic signaling within SGZ
microenvironment, and suggest that angiotensin II may participate in maintaining the basal rate of granule cell
neurogenesis.
Background
Sublethal doses of whole brain irradiation (WBI) are
commonly administered therapeutically (cranial radia-
tion), and might also be administered inadvertently in
the event of a nuclear accident or radiological attack
[1-3]. Clinical data derived from patients receiving cra-
nial radiation suggest that long term survivors of such
exposures are at risk for developing late delayed effects
manifesting as chronic and irreversible cognitive impair-
ment and dementia [3]. These late delayed effects are
routinely observed following WBI doses substantially
below thresholds for vasculopathy or demyelination, but
sufficient to impair granule cell neurogenesis within the
hippocampus along with electrophysiological and beha-
vioral measures of hippocampal plasticity [4-12]. These
observations suggest that impaired neurogenesis and
plasticity within the hippocampus may contribute to
cognitive impairment in humans exposed to WBI, and
that mitigating radiation damage to these progenitors
and/or preserving their neurogenic potential might be a
successful strategy for reducing the development of
these late delayed effects.
The learning and memory functions of the hippocam-
pus have been associated with a coordinated neurogenic
response that occurs within the subgranular zone (SGZ)
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adult brain (the other being the subventricular zone)
where the capacity for neurogenesis is retained through-
out life [4,13,14]. The unique microenvironment within
the SGZ induces vascular adventitial stem cells to differ-
entiate into rapidly dividing progenitors, which are typi-
cally found in discrete clusters surrounding their source
microvessels [4,5,15]. Signaling within the SGZ microen-
vironments defined by these clusters is required for neu-
ronal differentiation among the progenitors and
coordinates the rate of neurogenesis with the demands
of hippocampally-mediated learning and memory pro-
cesses [13,14]. Immature neurons may then migrate
away from these clusters into the adjacent granule cell
layer (GCL) where they may gradually mature to assume
the morphological and functional characteristics of gran-
ule cell neurons [9,16]. The proportion of these neurons
that survive to become mature granule cell neurons is
generally small but can be increased by behavioral activ-
ity, including physical exercise, environmental enrich-
ment, and spatial learning [16]. During their maturation,
which requires approximately 65 days, these new neu-
rons are hyperexcitable and possess an enhanced poten-
tial for synaptic plasticity [11,16].
Ablating neurogenesis within the dentate gyrus
impairs hippocampal plasticity and performance in spa-
tial learning tasks, and the severity of this impairment is
proportional to the extent of damage specific to the
granule cell progenitor population [5,10,11,14,17]. Radia-
tion dose-dependent decreases in granule cell neurogen-
esis are well established following WBI and result from
the loss of neural progenitors, via apoptosis and mitotic
catastrophe, and a disruption of neurogenic signaling,
via the dispersion of progenitor clusters within the SGZ.
These pathologies are inversely correlated with radiation
dose-dependent increases in activated microglia within
the dentate gyrus [18]. In vitro studies have revealed
that activated microglia contribute to the disruption of
neurogenesis in this context by releasing interleukin-6
(IL-6), interleukin-1b (IL-1b), and tumor necrosis fac-
tor-a (TNF-a), proinflammatory cytokines which induce
a nonspecific decrease in cell survival as well as a selec-
tive decrease in neuronal differentiation among progeni-
tor cells [9,18]. Administering the anti-inflammatory
drug, indomethacin, or the PPARa agonist, fenofibrate,
prior to irradiation partially prevents microglial activa-
tion and the decrease in neurogenesis post-irradiation.
Thus reducing inflammation within the dentate gyrus
post-irradiation might similarly reduce the deleterious
effects of WBI on granule cell neurogenesis [9,19].
Inhibiting the renin-angiotensin system (RAS) has pro-
ven to be one of the more successful strategies for miti-
gating the development of late delayed effects following
WBI doses above the necrotic threshold [20-22].
Though traditionally viewed as a blood-borne hormonal
system, a number of intraorgan RASs have also been
identified [23]. In the brain, RAS components are loca-
lized in both neuronal and glial cells which release renin
and angiotensinogen. These peptides interact to produce
angiotensin I, a biologically inactive decapeptide that is
subsequently cleaved by angiotensin I converting
enzyme (ACE) to produce the effector octapeptide
angiotensin II (Ang II). Ang II is a potent vasopressor
that exerts its effects by binding to G-protein receptors,
AT1R and AT2R, which are broadly distributed in the
brain and particularly dense in the hippocampus [23].
After tissue injury, AT2Rs are upregulated and Ang II,
in combination with other cytokines and growth factors,
produces pro-apoptotic, pro-inflammatory, and pro-oxi-
dant effects that may participate in the development of
long term tissue injury [24-31]. RAS inhibitors act either
by inhibiting ACE (ACEi), thereby blocking the conver-
sion of Ang I to Ang II, or by antagonizing the binding
of Ang II with either of its receptor subtypes [23]. Using
the ACEi, ramipril, we previously reported that chronic
ramipril administration, initiated two weeks after 30 Gy
focal irradiation of the rat brain, significantly mitigates
the development of white matter necrosis in the optic
tract [20-22]. Here we report that ramipril, administered
24 hours post-WBI and maintained daily for 12 weeks,
reduces the deleterious effects of 10 Gy-WBI, but not
15 Gy-WBI, on neurogenesis in the rat dentate gyrus.
Ramipril also reduces the basal rate of granule cell neu-
rogenesis in unirradiated control rats, suggesting that
Ang II participates in maintaining granule cell
neurogenesis.
Methods
Adult male Fischer 344 rats (Charles River Breeding
Lab, Wilmington, MA) weighing between 200 and 240 g
were used in all experiments. All animal procedures
were performed in AAALAC accredited facilities, follow-
ing institutionally approved protocols, in accordance
with published recommendations for the proper care
and use of laboratory animals. Food and water were pro-
vided ad libitum and consumption rates monitored
daily. A total of 33 rats were randomly assigned to
Radiation Treatment groups receiving WBI at prescribed
doses of 0 (Control, n = 9), 10 Gy (n = 16), and 15 Gy
(n = 8). Each of these Radiation Treatment groups was
subdivided into drug treatment groups receiving either
ramipril (RAM) or vehicle only (RAD), administered
according to the same schedule. Ramipril therapy was
initiated 24 hours post-WBI, and maintained continu-
ously until sacrifice at 12 weeks post-WBI.
Rats were irradiated using a dedicated self-shielded
5000Ci
137Cs irradiator (Mark I, Model 68, J.L. Shepherd
and Associates, San Fernando, CA), with a primary
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dose field. Rats were anesthetized using ketamine (80
mg/kg) and xylazine (8 mg/kg) and positioned horizon-
tally with their heads at the midpoint of this field (cen-
tered 15 cm above the base and 6 cm forward of the
collimator face) to optimize uniformity of the dose dis-
tribution. Secondary lead shielding (1 cm thick) was
used to limit radiation exposure to structures outside
the brain including the jaw, pharynx, nose, and eyes.
The head was oriented such that the radioactive source
was lateral to the midline, with the 2 cm dose field
dimension encompassing the anterior-posterior extent
of the brain. To compensate for the affects of tissue
attenuation, the prescribed radiation dose was adminis-
tered bilaterally in two consecutive half-dose fractions.
The measured dose rate at the time of irradiation was
approximately 3.2 Gy/minute.
Ramipril treated rats (RAM subgroups) received a
daily ramipril dose of approximately 1.5 mg/kg delivered
by addition of the compound to their drinking water,
whereas untreated rats (RAD subgroups) received bottle
changes according the same schedule. The ramipril con-
centration in the drinking water was based on animal
weight and the average ad libitum water consumption
rate of approximately 20 ml/day measured among our
experimental animals. Ramipril is an ester-containing
prodrug that is rapidly absorbed after oral intake and its
absorption is not affected by food. Upon absorption,
ramipril is metabolized by the liver and converted into
its active form, ramiprilat, a potent ACE inhibitor. The
bioavailability of ramipril is highly predictable and the
stability of the drug in drinking water is superior to
other ACE inhibitors. The drug also has the demon-
strated ability to cross the blood-brain barrier, unlike
many other clinically available ACE inhibitors [32,33].
Rats were sacrificed under deep pentobarbital anesthe-
sia (80 mg/kg) by transcardial perfusion with saline (300
ml) followed by 10% neutral buffered formalin (300 ml).
Brains were removed and post-fixed overnight at 4°C in
10% neutral buffered formalin, coronally sectioned into
2 mm blocks, and processed for paraffin embedding.
Groups of four serial sections (7 μm thickness) were cut
at 50 μm intervals along the rostral caudal axis of the
hippocampus. Within each of these groups, one section
was stained with hematoxylin-eosin (H&E) for routine
histological assessment, whereas the three remaining
sections were stained immunohistochemically using
antibodies for Ki-67 (1:100, 60 min, Thermo Fisher
Scientific, Fremont, CA,), a selective marker of cellular
proliferation; doublecortin (DCX; 1:100, overnight at 4°
C, Santa Cruz Biotechnology, Santa Cruz, CA), a selec-
tive marker of immature neurons; and CD68 (1:200, 30
m i n ,A b DS e r o t e c ,O x f o r d ,U K )as e l e c t i v em a r k e ro f
activated microglia. Immunohistochemically stained
sections were counter-stained using either hematoxylin
(CD68) or DAPI (Ki-67 and DCX), as appropriate. For
immunohistochemical processing, sections were deparaf-
finized and rehydrated, boiled for 10 minutes in 10 mM
citrate buffer, incubated with primary antibodies, and
labeled with DAB (CD68; 4+ detection/Betazoid DAB:
Biocare Medical) or Cy3 (Ki-67 and DCX; 1:250 Alexa
555 secondary, Invitrogen) per manufacturer’s
instructions.
All analyses were performed by individuals naïve to
the experimental conditions using previously established
methods [6,8,34-36]. Cell counts were performed bilater-
ally and exhaustively at 400× within the designated
fields. Counts of Ki-67
+ proliferating cells were per-
formed within the SGZ (defined as the region extending
25 μm on either side of the border between the hilus
and the GCL), and were restricted to cells with uniform
cytoplasmic staining of a clearly demarcated spherical or
elliptical structure containing a spherical DAPI-stained
nucleus. Counts of DCX
+ immature neurons were per-
formed within the GCL and SGZ, and were restricted to
cells with uniform cytoplasmic staining of a clearly
demarcated spherical or pyramidal structure (often with
dendritic processes extending through the GCL toward
the molecular layer) containing a spherical DAPI-stained
nucleus. Counts of CD68
+ activated microglia were per-
formed within the GCL and SGZ, and were restricted to
cells with cytoplasmic staining of a small cell body and/
or microglial processes associated with an elliptical
nucleus. The length of the SGZ at the GCL-hilar boar-
d e ra n dt h ev o l u m eo ft h eS G Za n dG C Lw e r ec a l c u -
lated for each section from which counts were obtained.
SGZ lengths were used to standardize Ki-67 and DCX
counts as linear densities. The SGZ and GCL volumes
were used to normalize the CD68 counts as volume
densities [34,35]. (Fig. 1)
The average linear density of Ki-67
+ cells residing
within the SGZ and inferior margin of the GCL was
used as measure of granule cell progenitor proliferation
near the time of sacrifice for each rat. The average linear
density of DCX
+ cells residing within the SGZ and GCL
was used as a measure of neurogenic potential near the
time of sacrifice for each rat. The average volume den-
sity of CD68
+ cells residing within the SGZ and GCL
was used as a measure of microglial activation for each
rat. Group means and standard deviations were calcu-
lated from these data and, when necessary, log transfor-
mations were performed prior to analysis to adjust for
unequal variances. These averages were statistically ana-
lyzed using analysis of variance (ANOVA) and Student’s
t to test whether: 1. Granule cell progenitor proliferation
and/or neurogenesis were differentially affected in the
Control group by RAM (relative to vehicle only); 2.
Granule cell progenitor proliferation and/or
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WBI Radiation Treatment groups relative to Control; 3.
Decreases in granule cell progenitor proliferation and/or
neurogenesis in the 10 Gy- and 15 Gy-WBI Radiation
Treatment groups were reduced by RAM (relative to
vehicle only); and 4. Microlglial activation was increased
in the 10 Gy- and 15 Gy-WBI Radiation Treatment
groups relative to Control and whether these increases
were reduced by RAM (relative to vehicle only) [37].
Results
Food and water intake and body weight among our ani-
mals were not affected by either radiation or ramipril
treatment during 12 weeks of monitoring post-irradia-
tion. In the Control group (CTL-SHAM), progenitor
proliferation (Ki-67) within the SGZ did not differ
between the Vehicle and RAM treatment groups; how-
ever, neurogenesis (DCX) was significantly (p < 0.05)
reduced by ramipril (Fig. 2). Ramipril (CTL-RAM) did
not affect the density of CD68
+ activated microglia rela-
tive to CTL-SHAM. Relative to Control, progenitor pro-
liferation and neurogenesis within the SGZ were
significantly reduced following 10 Gy- (p < 0.001), and
15 Gy-WBI (p < 0.001), accompanied by a significant
increase in CD68
+ activated microglia (p < 0.001). The
decrease in neurogenesis was radiation-dose dependent
(p < 0.01) (Fig. 2). Ramipril reduced the deleterious
effects of radiation on progenitor proliferation (p < 0.01)
and neurogenesis (p < 0.05) following 10 Gy-WBI, but
was not effective following 15 Gy-WBI (Fig. 1). The
mitigating effects of ramipril following 10 Gy-WBI were
not accompanied by significant reductions in CD68
+
activated microglia counts (Fig. 3).
Discussion
Our results add to a growing body of evidence suggest-
ing that RAS inhibitors can successfully reduce radia-
tion-induced late effects. As expected, based on previous
reports, 10 Gy- and 15 Gy-WBI produced dose-depen-
dent decreases in progenitor proliferation (Ki-67) and
neurogenesis (DCX) accompanied by a dose-dependent
increase in microglial activation within the dentate gyrus
[5,9,19]. Our use of the term neurogenesis here refers
specifically to the neurogenic potential of the SGZ, as
Figure 1 Representative images of immunohistochemical staining for Ki-67
+ progenitors (red), DCX
+ immature neurons (green), and
CD68
+ activated microglia (brown) in the SGZ and GCL, obtained at 400× from CLT-SHAM, 10 Gy, and 10 Gy-RAM group rats
sacrificed at 12 weeks post-irradiation. Note the robust progenitor and immature neuron production, and sparse activated microglia, in CTL-
SHAM tissue. Progenitor and immature neuron production are severely impaired, and activated microglia increased, in 10 Gy tissues. Impaired
progenitor and immature neuron production are subtly but significantly improved in 10 Gy-RAM tissue.
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and the production of immature DCX
+ neurons within
the SGZ microenvironment. Ramipril produced small
but significant mitigating effects when administered fol-
lowing 10 Gy-WBI, but was not effective when
administered following 15 Gy-WBI. The mitigating
effects of ramipril were more pronounced for progenitor
proliferation than they were for neurogenesis, suggesting
that they may be mediated primarily by reducing radia-
tion-induced apoptosis and/or mitotic catastrophes
Figure 2 Linear densities of Ki-67
+ progenitors and DCX
+ immature neurons within the SGZ at 12 weeks post-irradiation. A. Relative to
CTL-SHAM, Ki-67
+ progenitor proliferation is significantly (p < 0.001) reduced following 10 Gy- and 15 Gy-WBI. Ramipril mitigates the reduction
in Ki-67
+ progenitors following 10 Gy-WBI (p < 0.05), but not following 15 Gy-WBI. B. Relative to CTL-SHAM, DCX
+ immature granule cell neurons
are significantly (p < 0.001) and dose-dependently (p < 0.01) reduced following 10 Gy- and 15 Gy-WBI. Ramipril mitigates the reduction in
neurogenesis following 10 Gy-WBI (p < 0.05), but not following 15 Gy-WBI. Error bars represent the standard error of the mean for each
treatment group. (* = p < 0.05; ** = p < 0.01).
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effects of ramipril may act less potently to mitigate
radiation-induced disruption of neurogenic signaling
within the SGZ. Ang II, acting primarily via AT2R, is a
well established promoter of trauma-induced apoptosis
in a variety of tissues, including brain, and administering
AT2R antagonists has been shown to prevent Ang II-
induced apoptosis [24-26]. Thus, inhibiting the produc-
tion of Ang II with ramipril may similarly reduce apop-
tosis among neural progenitors within the SGZ
following radiation injury. The rather limited mitigating
effects produced by ramipril in this context may reflect
that fact that the majority of radiation-induced apoptosis
among progenitors within the SGZ occurs within 24
hours post-irradiation, preceding the initiation of rami-
pril therapy [35].
Cytostatic effects may also have contributed to the
mitigation produced by ramipril in this context. In the
Control group, ramipril significantly reduced neurogen-
esis without reducing progenitor proliferation within the
SGZ, suggesting that the signaling required for neuronal
(versus astrocytic) differentiation among these progeni-
tors was selectively inhibited by ramipril. Cytostatic
effects of ACEi and Ang II receptor antagonists are well
Figure 3 Volume densities of activated microglia measured within the SGZ and GCL at 12 weeks post-irradiation. A. Relative to CTL-
SHAM, CD68
+ activated microglia in the SGZ are significantly (p < 0.001) and dose-dependently increased following 10 Gy- and 15 Gy-WBI. B.
CD68
+ activated microglia are unaffected by ramipril in either the Control group (CTL-SHAM vs. CTL-AVS) or in the 10 Gy-WBR group (10 Gy vs.
10 Gy-AVS). Thus, the mitigating effects of ramipril on granule cell progenitor proliferation and neurogenesis following 10 Gy-WBI are not
accompanied by a decrease in activated microglia. Error bars represent the standard error of the mean for each treatment group.
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cells [38], and also in vivo where they arrest fibroblast
proliferation and regulate proliferation and migration of
endothelial cells [39]. Mukuda et al. [40] recently
reported that daily administration of the AT1R antago-
nist, losartan, maintained for 2 weeks suppresses run-
ning-enhanced increases in granule cell progenitor
proliferation in the rat SGZ without affecting the basal
proliferation rate. Ramipril’s suppression of the basal
rate of neurogenesis in the CTL-RAM group may reflect
its different mechanism of action, since ACE inhibitors
deprive both AT1R and AT2R of their substrate whereas
losartan antagonizes only the AT1R. Alternatively, it
may reflect the much longer duration of therapy and/or
t h er e l a t i v e l yh i g hd o s eo fr a m i p r i lu s e di no u rs t u d y ,
which was approximately twice the standard clinical
dose [41]. Both losartan and ramipril cross the blood-
brain barrier and are thus able to influence the brain
RAS system directly [42]. Ang II has been implicated as
a promoter of vascular endothelial growth factor
(VEGF) synthesis [41] and as a modulator of N-methyl-
D-aspartate (NMDA)-glutamate receptor function
[13,23]. Both of these processes are capable of acutely
affecting the rate of neurogenesis within the SGZ and
might therefore play a role in maintaining the basal rate
of neurogenesis as well [40].
The mitigating effects of ramipril following 10 Gy-
WBI were not accompanied by changes in the numbers
of activated microglia, suggesting that the anti-inflam-
matory effects of ramipril may not have played a signifi-
cant role. This observation lends additional support to
an anti-apoptotic mechanism being primary in this
regard. However, it is possible that ramipril produced
anti-inflammatory/anti-oxidant effects by antagonizing
the actions of IL-6, TNF-a,M C P - 1 ,o ro t h e rc y t o k i n e s ,
without affecting the numbers of activated microglia
[43]. It is also possible that radiation does not produce
deleterious effects on progenitor proliferation and/or
neuronal differentiation within the SGZ, but rather
selectively suppresses expression of the two proteins we
assayed as measures of these processes, i.e. Ki-67 and
CD68, respectively. However, the results of numerous
publications using a variety of assays for cellular prolif-
eration and granule cell neurogenesis suggest this as an
unlikely possibility [4-14]. Finally, the relevance of
impaired granule cell neurogenesis to late delayed cogni-
tive deficits has been called into question by recent
reports indicating that such deficits can manifest in
behavioral paradigms that are not conventionally viewed
as hippocampal-dependent and at very long latencies (>
3 months) post-irradiation [44].
Conclusions
Collectively our results add to the existing body of
knowledge regarding the radiation dose-dependence of
WBI effects on progenitor proliferation and neurogen-
esis within the SGZ, and establish that ramipril has the
capacity to reduce the deleterious effects of WBI in this
context. Though significant, the magnitude of these
effects does not suggest the treatment regimen
employed here as a promising therapeutic strategy in
this regard. However, it is possible that these assays are
not sufficiently inclusive and that the deleterious effects
of irradiation on other processes pertinent to learning
and memory are more potently mitigated by ramipril.
More potent mitigating effects might also be achieved
by administering ramipril at lower doses and/or for
shorter durations, or in combination with other anti-
apoptotic, anti-inflammatory or anti-oxidant therapies.
Addressing these experimental issues will be the focus
of future investigations.
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